CalciMedica (CALC) Preferred Stock Liabilities (2019 - 2022)
CalciMedica's (CALC) quarterly Preferred Stock Liabilities came in at $19.5 million in Q4 2022, down 85.16% on a QoQ basis from $131.4 million in Q2 2020.
CalciMedica (CALC) Preferred Stock Liabilities (2019 - 2022) Analysis & Trends
CalciMedica (CALC) has 3 years of Preferred Stock Liabilities data on file, last reported at $19.5 million in Q4 2022.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $19.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $19.5 million (changed N/A YoY) and the FY2022 annual result came in at $19.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $19.5 million in Q4 2022, from $131.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $131.4 million in Q3 2019 to a low of $19.5 million in Q4 2022.
- A 3-year average of $109.0 million and a median of $131.4 million in 2019 frame the typical range for Preferred Stock Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 19.49 Mn |
| Jun 30, 2020 | 131.36 Mn |
| Mar 31, 2020 | 131.36 Mn |
| Dec 31, 2019 | 131.36 Mn |
| Sep 30, 2019 | 131.36 Mn |